Eli Lilly is poised to add a new cancer arm to its drug lineup after entering advanced talks to buy Kelonia Therapeutics. The deal, valued at more than $2 billion, could close as early as Monday if negotiations hold steady. The acquisition would broaden Lilly’s oncology pipeline and strengthen its competitive edge.

Kelonia, a biotech focused on novel antibody‑drug conjugates, has generated buzz after preliminary trials showed promising results against solid tumors. Lilly’s interest reflects a broader push to capture high‑margin oncology assets. Investors view the move as a signal that the pharma giant is willing to spend aggressively on growth.

Deal terms include milestone payments that could lift the purchase price beyond the initial $2 billion figure. If Kelonia reaches predefined efficacy thresholds, Lilly would pay extra fees, potentially pushing the total to over $3 billion. Such earn‑outs are standard in biotech deals to align incentives.

The acquisition would position Lilly to compete more aggressively with rivals like Pfizer and Novartis, who have recently unveiled their own antibody‑drug conjugate programs. By integrating Kelonia’s platform, Lilly could accelerate clinical timelines and gain early access to breakthrough therapies, bolstering its long‑term revenue prospects.